首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1122375

肾癌治疗市场：按疗法、按药理学分类（血管生成抑製剂、mTOR 抑製剂、细胞因子等）、按分销渠道、按地区 - 规模、份额、前景、机会分析，2022-2030 年

Kidney Cancer Drugs Market, by Therapy, by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others ), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月03日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肾癌是一种肾细胞不受控制地生长、限制正常细胞功能的疾病。肾癌的风险因素包括吸烟、肥胖、工作场所接触镉、一些除草剂、有机溶剂，尤其是三氯乙烯、高血压、晚期肾病、某些药物、遗传和遗传风险因素。透明细胞肾细胞癌是最常见的肾细胞癌。在实验室观察时，构成透明细胞肾细胞癌的细胞看起来非常苍白或透明。在预测期内，这些风险因素的暴露增加为肾癌治疗市场提供了有利可图的增长前景。根据美国癌症协会 2018 年 1 月的数据调查，肾癌是美国男性和女性最常见的 10 种癌症之一。男性患肾癌的风险更高，大约每 48 名男性中有 1 人和每 83 名女性中有 1 人面临终生患肾癌的风险。肾细胞癌 (RCC) 是最常见的肾癌类型。相同的数据还表明，10 个肾癌中约有 9 个是肾细胞癌。

市场动态

主要参与者正在努力开发癌症免疫治疗药物，以对抗癌症并提高免疫力。例如，2019 年 1 月，医疗保健公司 F. Hoffmann-La Roche 宣布发现 PD-L1，一种防止癌症免疫逃逸的配体，可用作肾细胞癌治疗的辅助治疗。 Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A)，一种靶向程序性死亡配体 1) 的人工单克隆抗体。 Tecentriq 处于 III 期试验阶段。

本研究的主要特点

本报告对全球肾癌药物市场进行了深入分析，显示了市场规模（十亿美元）和復合年增长率 (CAGR%)。
它还揭示了不同细分市场的潜在收入机会，并概述了一个有吸引力的市场投资建议矩阵。
它还提供有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争策略等方面的重要见解。
它根据以下参数描述全球肾癌治疗市场的主要参与者 - 公司简介、产品组合、主要亮点、财务业绩和战略。
本研究涵盖的主要公司包括辉瑞公司、诺华国际公司、基因泰克公司、Active Biotech AB、安进公司、拜耳公司、Cipla Limited、霍夫曼拉罗氏公司、百时美施贵宝公司、卫材株式会社和 Exelixis, Inc.
我们相信，这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球肾癌治疗市场报告针对该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师1。
利益相关者可以通过用于分析全球肾癌治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场快照：按疗法分类
- 市场快照：按药理学分类
- 市场快照：按销售渠道
- 市场概况：按地区划分
连贯的机会图 (COM)

第 3 章市场动态、法规和趋势分析

市场动态
- 驱动程序
- 约束因素
- 市场机会
影响分析
市场趋势
流行病学
主要发展状况
战略联盟和收购
监管场景
保险报销分析
管道分析

第 4 章全球肾癌药物市场：冠状病毒 (COVID-19) 大流行的影响

整体影响
政府举措
COVID-19 对市场的影响

第 5 章全球肾癌药物市场：按疗法，2017-2030 年

靶向治疗
免疫疗法
化疗

第 6 章全球肾癌药物市场：按药理学分类，2017-2030

血管生成抑製剂
mTOR 抑製剂
其他（免疫检查点抑製剂、CTLA-4 抑製剂、抗代谢物等）

第 7 章。全球肾癌药物市场：按分销渠道，2017-2030 年

医院药房
零售药房
在线药店

第 8 章全球肾癌药物市场：2017-2030 年各地区

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
英国
德国
意大利
法国
西班牙
俄罗斯
其他欧洲
亚太地区
中国
印度
日本
东盟
澳大利亚
韩国
其他亚太地区
中东
海合会
以色列
其他中东
非洲
北非
中非
南非

第 9 章竞争格局

热图分析
公司简介
- 辉瑞公司
药物组合
- 诺华国际公司
医药产品组合
- 基因泰克公司
医药产品组合
- Active Biotech AB
医药产品组合
- 安进公司
医药产品组合
- 拜耳公司
药物组合
- Cipla 有限公司
药物组合
- 霍夫曼-拉罗氏公司
药物组合
- 百时美施贵宝公司
药物组合
- 卫材株式会社
药物组合
- Exelixis, Inc.
药物组合

第 10 章

参考资料
调查方法

简介目录

Product Code: CMI2399

Kidney cancer or renal carcinoma affects kidney cells to grow out of control and restrict the function of normal cells. Several risk factors associated with kidney cancer include smoking, obesity, workplace exposures substances such as cadmium, some herbicides, and organic solvents, particularly trichloroethylene, high blood pressure, advanced kidney disease, certain medicines, and genetic and hereditary risk factors. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure of these risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period. According to American Cancer Society, January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.

Market Dynamics

Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.

Key features of the study:

This report provides an in-depth analysis of the global kidney cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation:

Global Kidney Cancer Drugs Market, By Therapy:
- Targeted Therapy
- Immunotherapy
- Chemotherapy
Global Kidney Cancer Drugs Market, By Pharmacological Class:
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
Global Kidney Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Kidney Cancer Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Pfizer Inc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis International AG
- Genentech, Inc.
- Active Biotech AB
- Amgen Inc.
- Bayer AG
- Cipla Limited
- Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Exelixis, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacologic Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Epidemiology
Key Developments
Strategic Collaborations & Acquisitions
Regulatory Scenario
Reimbursement Analysis
Pipeline Analysis

4. Global Kidney Cancer Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Kidney Cancer Drugs Market, By Therapy, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Kidney Cancer Drugs Market, By Pharmacologic Class, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Kidney Cancer Drugs Market, By Region, 2017 - 2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacologic Class, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
North Africa
Central Africa
South Africa